Company Description
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A.
Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017.
The company was incorporated in 1995 and is headquartered in Richmond, California.
| Country | United States |
| Founded | 1995 |
| IPO Date | Apr 6, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Alexander Macrae |
Contact Details
Address: 501 Canal Blvd Richmond, California 94804 United States | |
| Phone | 510 970 6000 |
| Website | sangamo.com |
Stock Details
| Ticker Symbol | SGMO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001001233 |
| CUSIP Number | 800677106 |
| ISIN Number | US8006771062 |
| Employer ID | 68-0359556 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | Chief Executive Officer, President and Director |
| Scott B. Willoughby | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Nathalie Dubois-Stringfellow Ph.D. | Senior Vice President and Chief Development Officer |
| Gregory Davis Ph.D. | Head of Research and Technology |
| Louise Wilkie | Head of Global Corporate Communications and Investor Relations |
| Phillip Ramsey | Chief Technical Officer |
| Stephanie J. Seiler CLP | Vice President and Head of Business Development and Alliance Management |
| David Ojala | Scientist II - Discovery and Translational Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 8-K | Current Report |
| May 13, 2025 | 424B5 | Filing |
| May 13, 2025 | 8-K | Current Report |
| May 13, 2025 | FWP | Free Writing Prospectus |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |